These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
620 related articles for article (PubMed ID: 19435402)
1. The role of transdermal buprenorphine in the treatment of cancer pain: an expert panel consensus. Pergolizzi JV; Mercadante S; Echaburu AV; Van den Eynden B; Fragoso RM; Mordarski S; Lybaert W; Beniak J; Orońska A; Slama O; Curr Med Res Opin; 2009 Jun; 25(6):1517-28. PubMed ID: 19435402 [TBL] [Abstract][Full Text] [Related]
2. Opioids and the management of chronic severe pain in the elderly: consensus statement of an International Expert Panel with focus on the six clinically most often used World Health Organization Step III opioids (buprenorphine, fentanyl, hydromorphone, methadone, morphine, oxycodone). Pergolizzi J; Böger RH; Budd K; Dahan A; Erdine S; Hans G; Kress HG; Langford R; Likar R; Raffa RB; Sacerdote P Pain Pract; 2008; 8(4):287-313. PubMed ID: 18503626 [TBL] [Abstract][Full Text] [Related]
3. Transdermal buprenorphine in cancer pain and palliative care. Sittl R Palliat Med; 2006; 20 Suppl 1():s25-30. PubMed ID: 16764218 [TBL] [Abstract][Full Text] [Related]
4. Long-term management of chronic pain with transdermal buprenorphine: a multicenter, open-label, follow-up study in patients from three short-term clinical trials. Likar R; Kayser H; Sittl R Clin Ther; 2006 Jun; 28(6):943-52. PubMed ID: 16860176 [TBL] [Abstract][Full Text] [Related]
5. Transdermal buprenorphine patches applied in a 4-day regimen versus a 3-day regimen: a single-site, Phase III, randomized, open-label, crossover comparison. Likar R; Lorenz V; Korak-Leiter M; Kager I; Sittl R Clin Ther; 2007 Aug; 29(8):1591-606. PubMed ID: 17919542 [TBL] [Abstract][Full Text] [Related]
6. Transdermal buprenorphine in clinical practice--a post-marketing surveillance study in 13,179 patients. Griessinger N; Sittl R; Likar R Curr Med Res Opin; 2005 Aug; 21(8):1147-56. PubMed ID: 16083522 [TBL] [Abstract][Full Text] [Related]
7. Clinical update on the pharmacology, efficacy and safety of transdermal buprenorphine. Kress HG Eur J Pain; 2009 Mar; 13(3):219-30. PubMed ID: 18567516 [TBL] [Abstract][Full Text] [Related]
8. Transdermal buprenorphine in the treatment of chronic pain: results of a phase III, multicenter, randomized, double-blind, placebo-controlled study. Sorge J; Sittl R Clin Ther; 2004 Nov; 26(11):1808-20. PubMed ID: 15639693 [TBL] [Abstract][Full Text] [Related]
9. Effectiveness and tolerability of the buprenorphine transdermal system in patients with moderate to severe chronic pain: a multicenter, open-label, uncontrolled, prospective, observational clinical study. Muriel C; Failde I; Micó JA; Neira M; Sánchez-Magro I Clin Ther; 2005 Apr; 27(4):451-62. PubMed ID: 15922818 [TBL] [Abstract][Full Text] [Related]
10. Transdermal buprenorphine in the treatment of chronic pain. Sittl R Expert Rev Neurother; 2005 May; 5(3):315-23. PubMed ID: 15938664 [TBL] [Abstract][Full Text] [Related]
11. Opioid rotation from high-dose morphine to transdermal buprenorphine (Transtec) in chronic pain patients. Freye E; Anderson-Hillemacher A; Ritzdorf I; Levy JV Pain Pract; 2007 Jun; 7(2):123-9. PubMed ID: 17559481 [TBL] [Abstract][Full Text] [Related]
12. Equipotent doses of transdermal fentanyl and transdermal buprenorphine in patients with cancer and noncancer pain: results of a retrospective cohort study. Sittl R; Likar R; Nautrup BP Clin Ther; 2005 Feb; 27(2):225-37. PubMed ID: 15811486 [TBL] [Abstract][Full Text] [Related]
13. Transdermal buprenorphine in pain management--experiences from clinical practice: Five case studies. Louis F Int J Clin Pract; 2006 Oct; 60(10):1330-4. PubMed ID: 16981980 [TBL] [Abstract][Full Text] [Related]
14. Gastrointestinal symptoms under opioid therapy: a prospective comparison of oral sustained-release hydromorphone, transdermal fentanyl, and transdermal buprenorphine. Wirz S; Wittmann M; Schenk M; Schroeck A; Schaefer N; Mueller M; Standop J; Kloecker N; Nadstawek J Eur J Pain; 2009 Aug; 13(7):737-43. PubMed ID: 18977159 [TBL] [Abstract][Full Text] [Related]
15. [Post marketing surveillance study with an analgesic (transdermal buprenorphine patch) in patients with moderate to severe chronic pain]. Tschirner M; Ritzdorf I; Brünjes R MMW Fortschr Med; 2008 Sep; 150 Suppl 3():142-8. PubMed ID: 19025217 [TBL] [Abstract][Full Text] [Related]
16. Changes in the prescribed daily doses of transdermal fentanyl and transdermal buprenorphine during treatment of patients with cancer and noncancer pain in Germany: results of a retrospective cohort study. Sittl R; Nuijten M; Nautrup BP Clin Ther; 2005 Jul; 27(7):1022-31. PubMed ID: 16154481 [TBL] [Abstract][Full Text] [Related]
17. Safety and effectiveness of intravenous morphine for episodic breakthrough pain in patients receiving transdermal buprenorphine. Mercadante S; Villari P; Ferrera P; Porzio G; Aielli F; Verna L; Casuccio A J Pain Symptom Manage; 2006 Aug; 32(2):175-9. PubMed ID: 16877185 [TBL] [Abstract][Full Text] [Related]
18. Buprenorphine TDS: use in daily practice, benefits for patients. Radbruch L Int J Clin Pract Suppl; 2003 Feb; (133):19-22; discussion 23-4. PubMed ID: 12665120 [TBL] [Abstract][Full Text] [Related]
19. Transdermal opioids for cancer pain. Cachia E; Ahmedzai SH Curr Opin Support Palliat Care; 2011 Mar; 5(1):15-9. PubMed ID: 21325999 [TBL] [Abstract][Full Text] [Related]
20. Opioids in the management of chronic non-cancer pain: an update of American Society of the Interventional Pain Physicians' (ASIPP) Guidelines. Trescot AM; Helm S; Hansen H; Benyamin R; Glaser SE; Adlaka R; Patel S; Manchikanti L Pain Physician; 2008 Mar; 11(2 Suppl):S5-S62. PubMed ID: 18443640 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]